Altasciences and Evidence Matters Advance AI‑Driven Drug Development With Nonclinical Automation Breakthrough

Altasciences and Evidence Matters have successfully extended Evidence Matters' AI‑driven RegulatoryFlow ("RegFlow") platform from clinical reporting into nonclinical workflows, marking a significant automation breakthrough in early-phase drug development.

In a proof-of-concept, RegFlow demonstrated high‑quality parsing of raw and SEND nonclinical datasets and the ability to generate roughly one‑third of a typical nonclinical report with high fidelity, including structured results and focused laboratory sciences sections.

This integration aligns with Altasciences’ Acceleration Platform, which aims to compress the timeline from first safety assessments to clinical proof‑of‑concept by synchronizing nonclinical, clinical, bioanalytical, and manufacturing activities and using AI to streamline regulatory writing and reporting.